ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
TEMPORARY UNAVAILABILITY OF NATESTO® IN CANADA AND SOUTH KOREA
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 223797" data-attributes="member: 13851"><p>[URL unfurl="true"]https://calgarysun.com/globe-newswire/acerus-reports-first-quarter-2022-financial-results[/URL]</p><p></p><p></p><p><strong>Natesto®</strong></p><p></p><p><em>The Company is executing its commercial strategy focused on expanding in the US market. <strong>Total Natesto prescriptions rose 43% compared to the first quarter of 2021 and the Company expects continued growth in year over year prescriptions for the balance of 2022. </strong>The Company expects to expand its US sales footprint later in 2022 in anticipation of the return of Noctiva to the US market. Acerus believes that there is significant overlap in physician call points for both Natesto and Noctiva and this synergy will allow for better utilization and productivity of both existing and anticipated new sales staff hires.</em></p><p></p><p></p><p><strong><em>*Commercial preparations are in place for the reintroduction of Natesto® into the Canadian market, which has been somewhat hampered by <u>manufacturing and supply chain disruptions</u>. <u>The rollout is still anticipated to commence in the second half of 2022</u></em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 223797, member: 13851"] [URL unfurl="true"]https://calgarysun.com/globe-newswire/acerus-reports-first-quarter-2022-financial-results[/URL] [B]Natesto®[/B] [I]The Company is executing its commercial strategy focused on expanding in the US market. [B]Total Natesto prescriptions rose 43% compared to the first quarter of 2021 and the Company expects continued growth in year over year prescriptions for the balance of 2022. [/B]The Company expects to expand its US sales footprint later in 2022 in anticipation of the return of Noctiva to the US market. Acerus believes that there is significant overlap in physician call points for both Natesto and Noctiva and this synergy will allow for better utilization and productivity of both existing and anticipated new sales staff hires.[/I] [B][I]*Commercial preparations are in place for the reintroduction of Natesto® into the Canadian market, which has been somewhat hampered by [U]manufacturing and supply chain disruptions[/U]. [U]The rollout is still anticipated to commence in the second half of 2022[/U][/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
TEMPORARY UNAVAILABILITY OF NATESTO® IN CANADA AND SOUTH KOREA
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top